What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Four analysts have provided ratings for Ligand Pharmaceuticals (NASDAQ:LGND) over the past quarter, all maintaining a 'Buy' rating. The average 12-month price target has decreased by 6.4% to $119.5. Despite a decline in revenue, the company shows strong net margins and effective asset utilization.
June 28, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have maintained 'Buy' ratings for Ligand Pharmaceuticals with an average price target of $119.5, down 6.4% from the previous target. The company faces revenue decline but shows strong net margins and effective asset utilization.
All four analysts have maintained a 'Buy' rating, indicating positive sentiment. However, the average price target has decreased by 6.4%, reflecting some caution. The company's strong net margins and effective asset utilization are positive indicators, despite the revenue decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100